Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 2,515 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Healthy Volunteers
Interventions: Fedratinib, Digoxin, Rosuvastatin, Metformin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Respiratory Failure, Dyspnea During Mechanical Ventilation, Mechanical Ventilation
Interventions: Change to VC/AC, Change in Tidal Volume, Change in inspiratory flow, Change in PEEP, Change to PSV; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Traumatic Brain Injury, Aging Disorder, Magnetic Resonance Imaging (MRI)
Interventions: Hypercapnia task performed during fMRI; Other
Lead sponsor: Andrew Mayer; Other
Eligibility: 18 Years to 82 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Cerebrovascular Accident, Moyamoya Disease
Interventions: Xenon contrast agent, Magnetic Resonance Imaging; Drug · Device
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
Interventions: BAY2927088, Midazolam; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Full Thickness Rotator Cuff Tear
Interventions: Postoperative Jackins Exercise Protocol, Postoperative Pulleys Exercise Protocol; Procedure
Lead sponsor: Orthopedic Institute, Sioux Falls, SD; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Healthy Volunteer
Interventions: ABBV-903, Placebo for ABBV-903, Itraconazole; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Atropine Bioequivalence
Interventions: Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL); Drug
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Essential Tremor
Interventions: Acamprosate, Placebo, Methazolamide; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: West Bloomfield, Michigan

Conditions: Healthy Volunteer
Interventions: S-888711, Calcium Antacid; Drug · Dietary Supplement
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD, NASH
Interventions: Hyperpolarized (HP) 13C, Hyperpolarized 13C-Urea, Magnetic Resonance Imaging, Saline Flush; Drug · Procedure
Lead sponsor: Michael Ohliger, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: LY4100511 (DC-853) Dose 1, LY4100511 (DC-853) Dose 2, LY4100511 (DC-853) Dose 3, Midazolam, Repaglinide, Digoxin, Rosuvastatin; Drug
Lead sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pre Diabetes
Interventions: Fos Biomedical patch product, Fos Biomedical patch product:placebo; Device
Lead sponsor: Griffin Hospital; Other
Eligibility: 40 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Advanced Solid Tumors
Interventions: Tesetaxel, Itraconazole, Rifampin; Drug
Lead sponsor: Odonate Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Dallas, Texas • San Antonio, Texas

Conditions: Breast Cancer, Fatigue
Interventions: Iyengar Yoga, Wellness Seminar Series; Other
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteer
Interventions: cobimetinib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Palbociclib Formulation Reference, Palbociclib Formulation Test; Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: Febuxostat XR 80 mg Capsule F1, Febuxostat XR 80 mg Capsule F2, Febuxostat XR 80 mg Capsule F3, Febuxostat XR 80 mg Capsule F4; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chronic Kidney Disease, Chronic Renal Disease
Interventions: Dialysis Flow Rate Start 600mL/min, Dialysis Flow Rate Start 800mL/min; Other
Lead sponsor: Vantive Health LLC; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Sacramento, California • Louisville, Kentucky • Nashville, Tennessee

Conditions: Fungal Infections
Interventions: Posaconazole; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 2 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-955176, Placebo (Part 1), BMS-955176, Moxifloxacin, Placebo (Part 2); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 315 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Visual Acuity
Interventions: Test Contact Lens, Control Contact Lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 7
States / cities: Birmingham, Alabama • Jacksonville, Florida • Sarasota, Florida + 4 more

Conditions: Healthy
Interventions: TD-1211, TD-1211+ itraconazole; Drug
Lead sponsor: Glycyx Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Multiple Sclerosis
Interventions: peginterferon beta-1a, Rebif; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Evansville, Indiana

Search by objective public record fields.

Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin

Mechanical Ventilator Adjustments and Patient Dyspnea

Carbon Dioxide Administration and Brain Waste Clearance

Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients

A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

Effectiveness Study of Postoperative Rotator Cuff Repair Rehabilitation

A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

Acamprosate and Methazolamide for Essential Tremor

Effect of Food and Calcium on Pharmacokinetics of a Single Dose of S-888711 in Healthy Adult Volunteers

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants

Effects of Fos Biomedical Device on Diabetes Risk Factors and Sleep Quality in Adults at Risk for Type 2 Diabetes

The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors

A Yoga and Wellness Program for Breast Cancer Survivors With Persistent Fatigue

A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation

A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract

Phase 1, Febuxostat XR Relative Bioavailability Study

Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate

Genetic Variation and Variability in Posaconazole Pharmacokinetics in Children

A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects

Clinical Evaluation of Approved Contact Lenses

A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers